Device Offers Potential for More Effective Blood Disorders Diagnostics
|
By LabMedica International staff writers Posted on 23 Aug 2016 |

Image: The new device emulates the interface between the endothelium and circulating blood, opening new doors to diagnosing blood clotting diseases caused by dysfunction or inflammation of endothelial cells, which line all blood vessels and influence the process of hemostasis (Image courtesy of the Wyss Institute at Harvard University).
Researchers have developed a microfluidic device with fixed endothelial cells to mimic cellular and vascular flow conditions inside a patient’s body, which could help monitor blood clot formation, diagnose effectiveness of anti-platelet therapy, and prevent dysfunctional hemostasis.
When in dysfunction, the vascular endothelium (tissue that lines the blood vessels) plays a major role in the development of many diseases because endothelial cells are sensitive to blood flow and interact with blood cells through surface molecules. In normal hemostasis, the endothelium prevents life-threatening blood loss and clot formation, but dysfunction or inflammation may result in aberrant blood coagulation leading to blockages or hemorrhage.
"Abnormal blood coagulation and platelet activation are major medical problems and the ways we study them now are overly simplified," said Prof. Donald Ingber, MD, PhD, founding directlor of the Wyss Institute for Biologically Inspired Engineering at Harvard University (Boston, MA, USA), "Clinicians currently do not have tools to monitor hemostasis that take into account physiologically important interactions between endothelial cells and flowing blood."
The crucial interface between endothelial cells and circulating blood has not been replicated in a practical diagnostic device due to the challenge of incorporating living endothelial cells into a robust testing tool. In the new study, a Wyss Institute team led by Prof. Ingber has discovered that endothelial cells need not be “living” in order to confer their effects on blood coagulation. By microengineering tiny hollow channels lined by chemically fixed human endothelial cells that mimic cellular and vascular flow conditions inside a patient’s body, a new device developed by the team could monitor blood clot formation and diagnose effectiveness of anti-platelet therapy.
"It’s a bioinspired device that contains the endothelial function of a diseased patient without having actual living cells, and this greatly increases the robustness of the device," said first author Abhishek Jain, PhD, assistant professor at Texas A&M University, former Wyss Institute postdoctoral fellow.
This blood coagulation diagnostic can even be used to study the effects of endothelial inflammation on the formation of blood clots, which is highly relevant in patients suffering from atherosclerosis.
"This is one of the first examples of how a microfluidic cell culture system could have added value in clinical diagnostics,” said study co-author Andries van der Meer, PhD, former Wyss Institute postdoctoral fellow, now assistant professor at University of Twente, The Netherlands, “Using chemically fixed tissue that is no longer alive offers a clear, low-risk path toward further testing and product development."
A previous study by Prof. Ingber and team showed that recreating the physicality and blood flow of vasculature within microfluidic channels allowed them to predict precise times that blood might clot, with potential applications in real-time monitoring of patients receiving intravenous anticoagulants in order to prevent complications such as stroke and vascular occlusion. The new device adds another layer of complexity by embedding the functionality of the vascular endothelium within a diagnostic tool that might be manufactured, stored, and shipped for clinical use, which was not considered possible.
"Our efforts to mimic the vascular system in a meaningful way within a microfluidic device has led to two avenues of technology development," said Prof. Ingber, "Together they represent a new suite of physiologically relevant microdevices."
The study, by Jain A et al, was published online July 27, 2016, in the journal Biomedical Microdevices.
Related Links:
Wyss Institute for Biologically Inspired Engineering
When in dysfunction, the vascular endothelium (tissue that lines the blood vessels) plays a major role in the development of many diseases because endothelial cells are sensitive to blood flow and interact with blood cells through surface molecules. In normal hemostasis, the endothelium prevents life-threatening blood loss and clot formation, but dysfunction or inflammation may result in aberrant blood coagulation leading to blockages or hemorrhage.
"Abnormal blood coagulation and platelet activation are major medical problems and the ways we study them now are overly simplified," said Prof. Donald Ingber, MD, PhD, founding directlor of the Wyss Institute for Biologically Inspired Engineering at Harvard University (Boston, MA, USA), "Clinicians currently do not have tools to monitor hemostasis that take into account physiologically important interactions between endothelial cells and flowing blood."
The crucial interface between endothelial cells and circulating blood has not been replicated in a practical diagnostic device due to the challenge of incorporating living endothelial cells into a robust testing tool. In the new study, a Wyss Institute team led by Prof. Ingber has discovered that endothelial cells need not be “living” in order to confer their effects on blood coagulation. By microengineering tiny hollow channels lined by chemically fixed human endothelial cells that mimic cellular and vascular flow conditions inside a patient’s body, a new device developed by the team could monitor blood clot formation and diagnose effectiveness of anti-platelet therapy.
"It’s a bioinspired device that contains the endothelial function of a diseased patient without having actual living cells, and this greatly increases the robustness of the device," said first author Abhishek Jain, PhD, assistant professor at Texas A&M University, former Wyss Institute postdoctoral fellow.
This blood coagulation diagnostic can even be used to study the effects of endothelial inflammation on the formation of blood clots, which is highly relevant in patients suffering from atherosclerosis.
"This is one of the first examples of how a microfluidic cell culture system could have added value in clinical diagnostics,” said study co-author Andries van der Meer, PhD, former Wyss Institute postdoctoral fellow, now assistant professor at University of Twente, The Netherlands, “Using chemically fixed tissue that is no longer alive offers a clear, low-risk path toward further testing and product development."
A previous study by Prof. Ingber and team showed that recreating the physicality and blood flow of vasculature within microfluidic channels allowed them to predict precise times that blood might clot, with potential applications in real-time monitoring of patients receiving intravenous anticoagulants in order to prevent complications such as stroke and vascular occlusion. The new device adds another layer of complexity by embedding the functionality of the vascular endothelium within a diagnostic tool that might be manufactured, stored, and shipped for clinical use, which was not considered possible.
"Our efforts to mimic the vascular system in a meaningful way within a microfluidic device has led to two avenues of technology development," said Prof. Ingber, "Together they represent a new suite of physiologically relevant microdevices."
The study, by Jain A et al, was published online July 27, 2016, in the journal Biomedical Microdevices.
Related Links:
Wyss Institute for Biologically Inspired Engineering
Latest Technology News
- Robotic Technology Unveiled for Automated Diagnostic Blood Draws
- ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
- Aptamer Biosensor Technology to Transform Virus Detection
- AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
- AI-Generated Sensors Open New Paths for Early Cancer Detection
- Pioneering Blood Test Detects Lung Cancer Using Infrared Imaging
- AI Predicts Colorectal Cancer Survival Using Clinical and Molecular Features
- Diagnostic Chip Monitors Chemotherapy Effectiveness for Brain Cancer
- Machine Learning Models Diagnose ALS Earlier Through Blood Biomarkers
- Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







